# A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

Study · id `cardio:ct-nct06200207` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06200207](<https://clinicaltrials.gov/study/NCT06200207>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06200207

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 673 participants.

## Technical summary

Registry record NCT06200207. Randomized; quadruple masking; primary purpose treatment. Start 2024-04-01 (actual); primary completion 2026-10-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 673 participants (planned count; ClinicalTrials.gov record NCT06200207, source copy `cardio:ctgov-nct06200207-2026-10-01`, retrieved 2026-10-26)
- Started: 2024-04-01 (actual) (ClinicalTrials.gov record NCT06200207, source copy `cardio:ctgov-nct06200207-2026-10-01`, retrieved 2026-10-26)
- Primary completion: 2026-10-01 (anticipated) (ClinicalTrials.gov record NCT06200207, source copy `cardio:ctgov-nct06200207-2026-10-01`, retrieved 2026-10-26)
- Completion: 2027-01-08 (anticipated) (ClinicalTrials.gov record NCT06200207, source copy `cardio:ctgov-nct06200207-2026-10-01`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Bulgaria; Canada; Czechia; France; Germany; Greece; India; Malaysia; Poland; Portugal; Spain; Türkiye; United Kingdom (ClinicalTrials.gov record NCT06200207, source copy `cardio:ctgov-nct06200207-2026-10-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06200207-2026-10-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation
- Acronym: ATHENA
- Condition: Heart Failure
- Condition: Systemic Inflammation
- Intervention (Drug): Ziltivekimab
- Intervention (Drug): Placebo
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: e810a2a01aa734979cb2dda6b1694841a574240f3a120951f17ea477fe4a00dd
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
